Your browser doesn't support javascript.
loading
National action plans for antimicrobial resistance and variations in surveillance data platforms.
Pallett, Scott Jc; Charani, Esmita; Hawkins, Lois; Mazzella, Andrea; Anton-Vazquez, Vanesa; Banerjee, Rishi; Evans, Terry J; Patterson, Benjamin; Subbarao, Sathyavani; Alqahtani, Saleh; Basarab, Marina; Breathnach, Aodhan S; Mughal, Nabeela; Moore, Luke Sp.
Afiliação
  • Pallett SJ; Centre of Defence Pathology, Royal Centre for Defence Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, England.
  • Charani E; Centre of Excellence in Infectious Diseases Research, University of Liverpool, Liverpool, England.
  • Hawkins L; Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, England.
  • Mazzella A; Institute for Infection and Immunity, St George's University of London, London, England.
  • Anton-Vazquez V; Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, England.
  • Banerjee R; Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, England.
  • Evans TJ; Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, England.
  • Patterson B; Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, England.
  • Subbarao S; Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, England.
  • Alqahtani S; Medicine at Sibley Memorial Hospital, Johns Hopkins University, Baltimore, United States of America.
  • Basarab M; Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, England.
  • Breathnach AS; Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, England.
  • Mughal N; Clinical Infection Department, Chelsea and Westminster Hospital, London, England.
  • Moore LS; National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, England.
Bull World Health Organ ; 101(8): 501-512F, 2023 Aug 01.
Article em En | MEDLINE | ID: mdl-37529028
Objective: To assess how national antimicrobial susceptibility data used to inform national action plans vary across surveillance platforms. Methods: We identified available open-access, supranational, interactive surveillance platforms and cross-checked their data in accordance with the World Health Organization's (WHO's) Data Quality Assurance: module 1. We compared platform usability and completeness of time-matched data on the antimicrobial susceptibilities of four blood isolate species: Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pneumoniae from WHO's Global Antimicrobial Resistance and Use Surveillance System, European Centre for Disease Control's (ECDC's) network and Pfizer's Antimicrobial Testing Leadership and Surveillance database. Using Bland-Altman analysis, paired t-tests, and Wilcoxon signed-rank tests, we assessed susceptibility data and number of isolate concordances between platforms. Findings: Of 71 countries actively submitting data to WHO, 28 also submit to Pfizer's database; 19 to ECDC; and 16 to all three platforms. Limits of agreement between WHO's and Pfizer's platforms for organism-country susceptibility data ranged from -26% to 35%. While mean susceptibilities of WHO's and ECDC's platforms did not differ (bias: 0%, 95% confidence interval: -2 to 2), concordance between organism-country susceptibility was low (limits of agreement -18% to 18%). Significant differences exist in isolate numbers reported between WHO-Pfizer (mean of difference: 674, P-value: < 0.001, and WHO-ECDC (mean of difference: 192, P-value: 0.04) platforms. Conclusion: The considerable heterogeneity of nationally submitted data to commonly used antimicrobial resistance surveillance platforms compromises their validity, thus undermining local and global antimicrobial resistance strategies. Hence, we need to understand and address surveillance platform variability and its underlying mechanisms.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anti-Infecciosos / Antibacterianos Tipo de estudo: Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Bull World Health Organ Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anti-Infecciosos / Antibacterianos Tipo de estudo: Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Bull World Health Organ Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido